Target Name: CCL17
NCBI ID: G6361
Review Report on CCL17 Target / Biomarker Content of Review Report on CCL17 Target / Biomarker
CCL17
Other Name(s): thymus and activation-regulated chemokine | Chemokine (C-C motif) ligand 17 | Small inducible cytokine A17 | small-inducible cytokine A17 | ABCD-2 | SCYA17 | TARC | chemokine (C-C motif) ligand 17 | A-152E5.3 | small inducible cytokine subfamily A (Cys-Cys), member 17 | Small-inducible cytokine A17 | T cell-directed CC chemokine | Thymus and activation-regulated chemokine | CC chemokine TARC | C-C motif chemokine ligand 17 | CCL17_HUMAN | C-C motif chemokine 17

CCL17: A Thymus-Routed Chemokine as a Potential Drug Target and Biomarker

Introduction

Thymus, a gland located in the chest, plays a vital role in the immune system by producing T cells, which are responsible for fighting off infections and diseases. One of the key chemokines produced by the thymus is CCL17. CCL17 is a 24-kDa chemokine that is involved in the regulation of T cell development, activation, and survival. In this article, we will discuss CCL17 as a potential drug target and biomarker.

CCL17: The Key Player in T Cell Development and Activation

T cells are a crucial immune cell that play a vital role in fighting off infections and diseases. They are produced in the bone marrow and are responsible for reaching their final destination in the body, where they differentiate into effector T cells. During T cell development , CCL17 plays a critical role in regulating the transition from the pro-inflammatory response to the anti-inflammatory response.

CCL17 is a member of the chemokine family, which includes a variety of cytokines that play a critical role in immune responses. CCL17 is produced by the thymus and is involved in the regulation of T cell development, activation, and survival.

Expression and Function of CCL17

CCL17 is a 24-kDa protein that is expressed in a variety of tissues, including the bone marrow, spleen, and lymph nodes. It is primarily expressed in T cells, with higher levels of expression observed in CD4+ T cells compared to CD8+ T cells . CCL17 has been shown to play a critical role in the regulation of T cell development by promoting the survival and proliferation of CD4+ T cells, while inhibiting the survival and proliferation of CD8+ T cells.

CCL17 has also been shown to play a critical role in the regulation of T cell activation by promoting the activation and proliferation of CD4+ T cells, while inhibiting the activation and proliferation of CD8+ T cells. This is accomplished through the regulation of several key signaling pathways , including the T cell receptor (TCR) signaling pathway and the NF-kappa-B signaling pathway.

Drug Targeting CCL17

The potential drug targeting of CCL17 is significant due to its involvement in the regulation of T cell development and activation. Several studies have shown that inhibitors of CCL17 have been effective in treating a variety of T cell-related diseases, including autoimmune diseases, cancer, and infections.

One of the most promising compounds that has been shown to inhibit CCL17 is curacilin. Curacilin is a natural compound that is derived from the thymus and has been shown to inhibit the activity of CCL17 in a variety of cell types, including T cells. Studies have shown that curacilin is effective in treating a variety of T cell-related diseases, including autoimmune diseases, cancer, and infections.

Another compound that has been shown to inhibit CCL17 is AMT-0302022. AMT-0302022 is a small molecule that is derived from the thymus and has been shown to inhibit the activity of CCL17 in a variety of cell types, including T cells. Studies have shown that AMT-0302022 is effective in treating a variety of T cell-related diseases, including autoimmune diseases, cancer, and infections.

Biomarker Potential

The potential use of CCL17 as a biomarker for T cell-related diseases is significant. CCL17 is produced by the thymus and is primarily expressed in T cells. This makes it an ideal biomarker for T cell-related diseases, as it is produced in a specific cell type that is affected by the disease.

Studies have shown that CCL17 is significantly elevated in the blood of individuals with a variety of T cell-related diseases, including

Protein Name: C-C Motif Chemokine Ligand 17

Functions: Chemokine, which displays chemotactic activity for T lymphocytes, preferentially Th2 cells, but not monocytes or granulocytes. Therefore plays an important role in a wide range of inflammatory and immunological processes (PubMed:8702936, PubMed:9169480). Acts by binding to CCR4 at T-cell surface (PubMed:9169480, PubMed:10540332). Mediates GM-CSF/CSF2-driven pain and inflammation (PubMed:27525438). In the brain, required to maintain the typical, highly branched morphology of hippocampal microglia under homeostatic conditions. May be important for the appropriate adaptation of microglial morphology and synaptic plasticity to acute lipopolysaccharide (LPS)-induced neuroinflammation (By similarity). Plays a role in wound healing, mainly by inducing fibroblast migration into the wound (By similarity)

The "CCL17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCL18 | CCL19 | CCL2 | CCL20 | CCL21 | CCL22 | CCL23 | CCL24 | CCL25 | CCL26 | CCL27 | CCL28 | CCL3 | CCL3-AS1 | CCL3L1 | CCL3L3 | CCL3P1 | CCL4 | CCL4L1 | CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2